Prostate Cancer Treatment: Long-Term Data Reveals Nuances of Hormone Therapy
New long-term analysis of data from a landmark clinical trial, RTOG 9601, is refining our understanding of the role of hormone therapy alongside radiation for recurrent prostate cancer. Published in The Lancet, the research highlights the benefits of adding antiandrogen therapy (AAT) to salvage radiation therapy (RT) after radical prostatectomy, but also points to the importance of considering treatment duration and evolving standards of care.
The RTOG 9601 Study: A Foundation for Modern Treatment
The RTOG 9601 trial, conducted between 1998 and 2003, involved 760 men with prostate cancer recurrence following radical prostatectomy. Participants were randomly assigned to receive radiation therapy either with or without 24 months of bicalutamide, a type of antiandrogen therapy. Recent follow-up, with a median of 18.9 years, demonstrates a statistically significant improvement in overall survival for those receiving RT plus AAT. Specifically, 18-year overall survival was 53% for the combined therapy group versus 43% for radiation alone (adjusted HR = 0.82; 95% CI, 0.67-1.00).
The study also showed a reduction in prostate cancer deaths and metastatic disease in the group receiving hormone therapy alongside radiation. The 18-year incidence of prostate cancer deaths was 18% with RT + AAT compared to 28% with RT + placebo (unadjusted sHR = 0.63; 95% CI, 0.46-0.84). Similarly, the incidence of metastatic prostate cancer was lower in the AAT group (22%) versus the placebo group (31%) (unadjusted sHR = 0.62; 95% CI, 0.46-0.83).
Evolving Hormone Therapy Approaches
While the RTOG 9601 trial established a benefit for AAT, recent reports indicate that the landscape of hormone therapy is shifting. A significant portion of patients receiving long-term hormone therapy today were treated under the RTOG 9601 protocol, which utilized bicalutamide monotherapy. Modern approaches often involve different hormone therapies and may be combined with other treatments, like docetaxel, particularly for castration-resistant prostate cancer.
This evolution is crucial because the duration and type of hormone therapy can significantly impact outcomes and side effects. The individual patient data meta-analysis underscores the need to personalize treatment strategies based on individual risk factors and disease characteristics.
Did you know? Salvage radiation therapy is a common treatment option for men experiencing prostate cancer recurrence after initial treatment with radical prostatectomy.
Implications for Future Guidelines
The AUA/ASTRO/SUO guideline on salvage therapy for prostate cancer already acknowledges the survival advantage of concurrent AAT with salvage RT, citing both the RTOG 9601 and NRG/RTOG 0534 SPPORT studies. Yet, ongoing research continues to refine these recommendations.
The latest data emphasizes the importance of carefully considering the duration of hormone therapy and the potential benefits of newer agents. Future guidelines are likely to incorporate these nuances, providing clinicians with more precise tools for tailoring treatment plans to individual patients.
Pro Tip: Open communication with your oncologist is essential to understand the risks and benefits of all treatment options and to develop a personalized plan that aligns with your goals.
FAQ
Q: What is salvage radiation therapy?
A: Salvage radiation therapy is radiation treatment given after initial treatment (usually surgery) to eliminate remaining cancer cells.
Q: What is antiandrogen therapy (AAT)?
A: AAT uses medications to block the effects of male hormones (androgens) which can fuel prostate cancer growth.
Q: Is hormone therapy always necessary after prostatectomy?
A: Not always. The decision to use hormone therapy depends on factors like the stage of cancer, PSA levels, and the presence of positive margins after surgery.
Q: What were the key findings of the RTOG 9601 trial?
A: The trial demonstrated that adding antiandrogen therapy (bicalutamide) to radiation therapy improved overall survival and reduced the risk of cancer death and metastasis in men with recurrent prostate cancer.
Want to learn more about prostate cancer treatment options? Explore the AUA guidelines on salvage therapy.
